Fluconazole

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
76
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Vulvovaginal Candidiasis

Conditions

Vulvovaginal Candidiasis

Trial Timeline

Mar 5, 2013 โ†’ Nov 22, 2013

About Fluconazole

Fluconazole is a phase 3 stage product being developed by Pfizer for Vulvovaginal Candidiasis. The current trial status is completed. This product is registered under clinical trial identifier NCT01806623. Target conditions include Vulvovaginal Candidiasis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (14)

NCT IDPhaseStatus
NCT00002077Pre-clinicalCompleted
NCT00002306Pre-clinicalCompleted
NCT00000627Pre-clinicalCompleted
NCT00002040Pre-clinicalCompleted
NCT00002010Pre-clinicalCompleted
NCT00002325Pre-clinicalCompleted
NCT00000744Pre-clinicalCompleted
NCT00002339Phase 3Completed
NCT00002038Pre-clinicalCompleted
NCT00002294Pre-clinicalCompleted
NCT00002076Pre-clinicalCompleted
NCT01806623Phase 3Completed
NCT01680458Pre-clinicalCompleted
NCT00645242Phase 3Completed

Competing Products

10 competing products in Vulvovaginal Candidiasis

See all competitors
ProductCompanyStageHype Score
SHR8008 + FluconazoleJiangsu Hengrui MedicinePhase 3
77
SHR8008 capsule + Fluconazole capsuleJiangsu Hengrui MedicinePhase 3
77
Estradiol 10 MCG Vaginal Tablet [VAGIFEM] + Promestriene VaginalNovo NordiskPhase 3
76
Clotrimazole vaginal tablet + FluconazoleBayerApproved
82
SCY-078 + FluconazoleScynexisPhase 2
44
IbrexafungerpScynexisPhase 3
69
Fluconazole Tablet + IBREXAFUNGERP + Placebo oral tabletScynexisPhase 3
69
IbrexafungerpScynexisPhase 1
25
Estradiol + PlaceboTherapeuticsMDPhase 3
69
Oral Encochleated Amphotericin B (CAMB) + Oral Encochleated Amphotericin B (CAMB)Matinas BiopharmaPhase 2
44